What is Ocular Therapeutix's change in deferred revenue?

Ocular Therapeutix (OCUL) reported change in deferred revenue of -$64K in Q2 2025.

How has Ocular Therapeutix's change in deferred revenue changed year-over-year?

Ocular Therapeutix's change in deferred revenue decreased by 3.2% year-over-year, from -$62K to -$64K.

What does change in deferred revenue mean?

Change in payments received from customers for goods/services not yet delivered — a key SaaS and subscription metric.

Ocular Therapeutix OCUL Change in Deferred Revenue

Change in Deferred Revenue at other companies

Regeneron PharmaceuticalsREGN

$99.6M+463%

HRO

HarrowHROW

-$639K-733%

Ultragenyx PharmaceuticalRARE

$0+100%

TG TherapeuticsTGTX

-$5.99M-4,377%

Other financials

Income statement

See full

Revenue$10.8M+0.8%

Gross profit$9.5M+0.2%

Operating income-$93.3M-46.0%

Net income-$88.6M-38.3%

EPS (diluted)-$0.40-5.3%

Balance sheet

See full

Cash & equivalents$666.7M+90.7%

Total debt$79.5M+4.2%

Total equity$581.6M+119%

Total assets$732.5M+80.5%

Cash flow

See full

Operating cash flow-$66.0M-47.7%

CapEx$4.7M+141%

Free cash flow-$70.7M-51.6%

Valuation

See full

Market cap$2.21B+58.2%

Enterprise value$1.63B+40.8%

P/S42.6×+19.1×

Profitability

See full

Gross margin87.2%-3.4pp

Operating margin-575.4%+1,233pp

Net margin-558.2%+1,493pp

FCF margin-463%+2,860pp

Returns & leverage

See full

Return on equity-68.6%+17.0pp

Debt / equity0.1×-0.2×

Current ratio14.8×+4.6×

Where this comes from

Reported directly by Ocular Therapeutix in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInContractWithCustomerLiability.

The official record: Ocular Therapeutix’s 10-Q, filed August 5, 2025, on SEC EDGAR. View the filing →

Ask your AI about Ocular Therapeutix's change in deferred revenue.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Ocular Therapeutix's change in deferred revenue?: Ocular Therapeutix (OCUL) reported change in deferred revenue of -$64K in Q2 2025.
How has Ocular Therapeutix's change in deferred revenue changed year-over-year?: Ocular Therapeutix's change in deferred revenue decreased by 3.2% year-over-year, from -$62K to -$64K.
What does change in deferred revenue mean?: Change in payments received from customers for goods/services not yet delivered — a key SaaS and subscription metric.